TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07386743: A Multicenter, Randomized, Double-blinded, Parallel, Positive-controlled, Phase III Comparative Study to Evaluate GS101 Injection Versus Dupixent® in Participants With Moderate-to-Severe Atopic Dermatitis

Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 572 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,723,520

Rescue Site Savings

+$7,730,196

Unlock Full NCT07386743 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07386743 Rescue Dossier →